ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc.

Biotechnology: Pharmaceutical Preparations

Health Care

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

IPO Year:

Exchange: NASDAQ

Website: anixa.com

Recent Analyst Ratings for Anixa Biosciences Inc.

Date	Price Target	Rating	Analyst
3/21/2025	$10.00	Buy	Maxim Group
12/23/2022	$8.00	Buy	Chardan Capital Markets

See more ratings

Anixa Biosciences Inc.

Recent Analyst Ratings for Anixa Biosciences Inc.

Anixa Biosciences Inc.

Recent Analyst Ratings for Anixa Biosciences Inc.

Anixa Biosciences Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Baskies Arnold M bought $14,100 worth of shares (5,000 units at $2.82), increasing direct ownership by 4% to 120,000 units (SEC Form 4)

Director Titterton Lewis H Jr bought $8,820 worth of shares (3,000 units at $2.94), increasing direct ownership by 0.32% to 933,334 units (SEC Form 4)

Director Titterton Lewis H Jr bought $6,020 worth of shares (2,000 units at $3.01), increasing direct ownership by 0.22% to 930,334 units (SEC Form 4)

Director Titterton Lewis H Jr bought $15,540 worth of shares (6,000 units at $2.59), increasing direct ownership by 0.65% to 928,334 units (SEC Form 4)

Director Titterton Lewis H Jr bought $25,700 worth of shares (10,000 units at $2.57), increasing direct ownership by 1% to 922,334 units (SEC Form 4)

Chief Executive Officer Kumar Amit bought $95,890 worth of shares (43,000 units at $2.23), increasing direct ownership by 8% to 559,925 units (SEC Form 4)

President, COO, & CFO Catelani Michael bought $19,971 worth of shares (9,289 units at $2.15), increasing direct ownership by 26% to 44,500 units (SEC Form 4)

SEC Form 4 filed by Director Gottschalk Emily

SEC Form 4 filed by Chief Executive Officer Kumar Amit

SEC Form 4 filed by Director Baskies Arnold M

Anixa Biosciences Inc. Leadership Updates

Live Leadership Updates

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja

Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board

Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer

Anixa Biosciences Inc. Press Releases

Fastest customizable press release news feed in the world

Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Anixa Biosciences Inc. SEC Filings

Anixa Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Anixa Biosciences Inc.

SEC Form DEF 14A filed by Anixa Biosciences Inc.

SEC Form S-8 filed by Anixa Biosciences Inc.

SEC Form 10-K filed by Anixa Biosciences Inc.

Amendment: SEC Form SCHEDULE 13D/A filed by Anixa Biosciences Inc.

Anixa Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Anixa Biosciences Inc.

SEC Form 10-Q filed by Anixa Biosciences Inc.

Anixa Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

Anixa Biosciences Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Maxim Group initiated coverage on Anixa Biosciences with a new price target

Chardan Capital Markets initiated coverage on Anixa Biosciences with a new price target

HC Wainwright & Co. initiated coverage on Anixa Biosciences with a new price target

Anixa Biosciences Inc. Financials

Live finance-specific insights

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Anixa Biosciences Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

Director Baskies Arnold M bought $14,100 worth of shares (5,000 units at $2.82), increasing direct ownership by 4% to 120,000 units (SEC Form 4)

Director Titterton Lewis H Jr bought $8,820 worth of shares (3,000 units at $2.94), increasing direct ownership by 0.32% to 933,334 units (SEC Form 4)

Director Titterton Lewis H Jr bought $6,020 worth of shares (2,000 units at $3.01), increasing direct ownership by 0.22% to 930,334 units (SEC Form 4)

Director Titterton Lewis H Jr bought $15,540 worth of shares (6,000 units at $2.59), increasing direct ownership by 0.65% to 928,334 units (SEC Form 4)

Director Titterton Lewis H Jr bought $25,700 worth of shares (10,000 units at $2.57), increasing direct ownership by 1% to 922,334 units (SEC Form 4)

Chief Executive Officer Kumar Amit bought $95,890 worth of shares (43,000 units at $2.23), increasing direct ownership by 8% to 559,925 units (SEC Form 4)

President, COO, & CFO Catelani Michael bought $19,971 worth of shares (9,289 units at $2.15), increasing direct ownership by 26% to 44,500 units (SEC Form 4)

Director Titterton Lewis H Jr bought $84,260 worth of shares (27,226 units at $3.09), increasing direct ownership by 3% to 896,334 units (SEC Form 4)

Director Titterton Lewis H Jr bought $25,568 worth of shares (8,496 units at $3.01), increasing direct ownership by 0.99% to 869,108 units (SEC Form 4)

Director Baskies Arnold M bought $15,450 worth of shares (5,000 units at $3.09), increasing direct ownership by 5% to 115,000 units (SEC Form 4)

SEC Form SC 13D filed by Anixa Biosciences Inc.

SEC Form SC 13D/A filed by Anixa Biosciences Inc. (Amendment)

SEC Form SC 13D/A filed by Anixa Biosciences, Inc. (Amendment)

SEC Form SC 13D/A filed by Anixa Biosciences, Inc. (Amendment)

SEC Form SC 13D/A filed